Table 1 Baseline characteristics of cases and controls.
| Characteristics | Cases (n = 389) | Controls (n = 2344) | p Value |
|---|---|---|---|
| Age at index date, mean (SD) | 66.8 (11.7) | 66.0 (11.3) | 0.216 |
| Number of months between first MI and index date, mean (SD) | 32.6 (34.8) | 30.7 (32.6) | 0.32 |
| Men | 283 (72.8) | 1719 (73.3) | 0.809 |
| Women | 106 (27.2) | 625 (26.7) | |
| Drugs used between first MI and index date (PDC >70%) | |||
| Antiplatelet agent | 197 (50.6) | 1314 (56.1) | 0.047 |
| β Blocker | 216 (55.5) | 1199 (51.2) | 0.110 |
| ACE inhibitor | 88 (22.6) | 557 (23.8) | 0.624 |
| Statin | 51 (13.1) | 547 (23.3) | <0.001 |
| β Blocker and/or ACE inhibitor | 253 (65.0) | 1491 (63.6) | 0.587 |
| Comorbidity or comedication | |||
| Admission for CHF after first MI | 15 (3.9) | 67 (2.9) | 0.285 |
| PTCA or CABG procedure after first MI | 24 (6.2) | 190 (8.1) | 0.188 |
| Diabetes mellitus | 75 (19.3) | 361 (15.4) | 0.053 |
| Angina pectoris | 267 (68.6) | 1386 (59.1) | 0.000 |
| Use of antiarrhythmic drugs | 12 (3.1) | 102 (4.4) | 0.247 |
| Use of calcium channel blockers | 182 (46.8) | 951 (40.6) | 0.021 |
| Use of oral anticoagulants | 136 (35.0) | 865 (36.9) | 0.462 |
| Use of digoxin | 43 (11.1) | 233 (9.9) | 0.500 |
Results are shown as number (%) unless otherwise stated.
CABG, coronary artery bypass grafting; CHF, chronic heart failure; MI, myocardial infarction; PDC, percentage of days covered; PTCA, percutaneous transluminal coronary angioplasty.